trending Market Intelligence /marketintelligence/en/news-insights/trending/BSRYsOYXecYKC8nwSSIfhg2 content esgSubNav
In This List

IntelGenx's resubmitted application for migraine drug accepted by US FDA

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


IntelGenx's resubmitted application for migraine drug accepted by US FDA

IntelGenx Technologies Corp. said the U.S. Food and Drug Administration has accepted its resubmitted new drug application for Rizaport VersaFilm, an oral soluble film for acute migraine.

The Montreal-based pharmaceutical company resubmitted the application for the drug in September after it was rejected a second time by the regulator in April.

Earlier rejections by the FDA were based on the regulator's concerns regarding chemistry, manufacturing and controls. The agency also requested additional information regarding the treatment, a proprietary oral thin film formulation of rizatriptan benzoate — the active drug in Merck & Co. Inc.'s Maxalt.

IntelGenx develops oral films — treatments that dissolve in the mouth, delivering certain medicines — using its VersaFilm technology platform.